News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Subscribe

Spotlight -

2026 State of Pharmacy survey results available now|

Our March 2026 print pub|

AMCP Annual 2026

Opinion|Videos|August 5, 2024

Key Patient Factors in Determining an Optimal Biologic Therapy

Author(s)Jill Zouzoulas, MD, FACR, Tryon Medical Partners

An expert rheumatologist highlights the billing process for patients receiving biologic therapies, as well as a study that highlights patient reported outcomes in patients with inflammatory arthritis utilizing intravenous biologics.

Episodes in this series

EP. 1 Indication and Practical Utilization of IV and Subcutaneous Biologics

EP. 1 Indication and Practical Utilization of IV and Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 2 Key Consideration and Concerns Around IV and Subcutaneous Biologic Use

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 3 Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 4 Key Patient Factors in Determining an Optimal Biologic Therapy

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 5 Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 6 Future Predictions for Intravenous and Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 7 Overall Experience With Intravenous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 8 Clinical Insights With Subcutaneous Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 9 Innovations Associated With IV Biologics

Jill Zouzoulas, MD, FACR, an expert on biologic therapies

EP. 10 Exciting Developments With Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 11 Positioning Intravenous and Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 12 Adherence With Intravenous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 13 Billing With Intravenous and Subcutaneous Therapies

Jennifer Seminerio, MD, a gastroenterologist

EP. 14 Evaluating Efficacy Between Intravenous and Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 15 Cost Considerations With Intravenous and Subcutaneous Biologics

Jennifer Seminerio, MD, a gastroenterologist

EP. 16 Patient Experience With Intravenous and Subcutaneous Therapies

Jennifer Seminerio, MD, a gastroenterologist

EP. 17 Role of Biosimilars in Gastrointestinal Diseases

Jennifer Seminerio, MD, a gastroenterologist

EP. 18 Future Direction of Intravenous and Subcutaneous Biologics

EP. 19 K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies

EP. 19 K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies

Video content above is prompted by the following questions:

What is the difference in the billing process with IV and subQ therapies? What are the pros and cons of each?
Patient reported outcomes have been assessed for patients with inflammatory arthritis utilizing IV biologics. What did this study demonstrate and does it impact your clinical practice?

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Related Content

The value and cost-effectiveness of bispecific antibodies

ByC. Brooke Adams, Pharm.D., BCOP

May 20th 2026

Takeaways from the phase 1/2 LINKER-MM4 and other ongoing trials of early-line bispecific antibody treatment

ByC. Brooke Adams, Pharm.D., BCOP

May 20th 2026

Psychosocial Impacts and Traditional Treatment Modalities in Vitiligo

ByDavid Rosmarin, MD

May 18th 2026

Advantages of bispecific antibodies over triplet and quadruplet therapies

ByC. Brooke Adams, Pharm.D., BCOP

May 13th 2026

Patients who would benefit from early-line treatment bispecific antibodies

ByC. Brooke Adams, Pharm.D., BCOP

May 13th 2026

Latest CME

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

Go to PER in Chicago

In-Person + Virtual Event

Go to PER in Chicago

May 29-31, 2026

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

2-Part Webinar Series

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Lauren Averett Byers, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Trending on Managed Healthcare Executive

FDA approves first treatment for chronic hepatitis D virus

Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026

Langlara, third interchangeable biosimilar to Lantus, approved by FDA

Recent COVID vaccination cuts household transmission by half

Family healthcare costs reach $37,824, analysis finds